Can a smaller dose of this cancer drug still work? new trial aims to find out
NCT ID NCT07576725
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-cost dosing. The study will enroll 50 participants with cancers like melanoma, lung cancer, and kidney cancer that cannot be surgically removed or have spread.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab (a type of immunotherapy drug)
- What this could lead to
- If successful, this could show that a lower, less frequent dose of nivolumab works as well as the standard dose, making treatment more affordable and accessible worldwide.
- What could go wrong
- This is a small, early-phase trial (50 people) across many cancer types, so results may not apply to all. Lower dosing might be less effective or have different side effects than standard dosing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Uganda Cancer Institute
Kampala, 3935, Uganda
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a new blood test spot colorectal cancer return earlier?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Can a pill rewrite the genetic story of resistant kidney cancer?